Myelodysplastic syndromes: toward a risk-adapted treatment approach.
Publication/Presentation Date
10-1-2013
Abstract
Several classification and scoring systems have been developed in myelodysplastic syndromes (MDS to predict the risk of progression to acute myeloid leukemia and survival. These prognostication models have been also used to inform therapeutic decision-making in a risk-adapted fashion. Patient-related factors such as age, comorbidities, and functional status have to be considered as well. Here we review a risk-guided therapeutic approach for the management of MDS patients. It is anticipated that the improved understanding of the complex pathogenesis of MDS and the recent discovery of important molecular lesions will be translated into novel therapeutic approaches. Additionally, some prognostic aberrations are expected to be incorporated into the prognostic tools with the goal of improving their prognostic precision and therefore allow for a more informed therapeutic decision-making based on the individual's risk profile.
Volume
6
Issue
5
First Page
611
Last Page
624
ISSN
1747-4094
Published In/Presented At
Faltas, B., Zeidan, A., & Gergis, U. (2013). Myelodysplastic syndromes: toward a risk-adapted treatment approach. Expert review of hematology, 6(5), 611–624. https://doi.org/10.1586/17474086.2013.840997
Disciplines
Medicine and Health Sciences
PubMedID
24094045
Department(s)
Department of Medicine, Hematology-Medical Oncology Division, Lehigh Valley Topper Cancer Institute
Document Type
Article